Predictive and prognostic performance of sFlt-1/PlGF ratio for preeclampsia in women with singleton pregnancy in a tertiary care institution in Mexico

Etna Sahagún Preciado; Alfonso López Lerma; Diana L. Olmedo Mendez

doi:10.18203/2320-1770.ijrcog20264237

Authors

Etna Sahagún Preciado Department of Gynecology and Obstetrics, Instituto Mexicano del Seguro Social, Centro Médico Nacional de Occidente, Guadalajara, Jalisco, Mexico
Alfonso López Lerma Department of Gynecology and Obstetrics, Instituto Mexicano del Seguro Social, Centro Médico Nacional de Occidente, Guadalajara, Jalisco, Mexico
Diana L. Olmedo Mendez Department of Gynecology and Obstetrics, Instituto Mexicano del Seguro Social, Centro Médico Nacional de Occidente, Guadalajara, Jalisco, Mexico

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20264237

Keywords:

Preeclampsia, Soluble fms-like tyrosine kinase-1, Placental growth factor, Maternal outcomes, Neonatal outcomes

Abstract

Background: Preeclampsia is a complex hypertensive disorder of pregnancy characterized by placental dysfunction and maternal multiorgan injury. Circulating angiogenic and antiangiogenic biomarkers may improve risk stratification and prediction of adverse outcomes.

Methods: This retrospective cohort study evaluated the predictive and prognostic performance of the soluble fms-like tyrosine kinase-1 (sFlt-1)/placental growth factor (PlGF) ratio in patients with singleton pregnancy from 24 to 36 + 6 weeks who had clinical or biochemical suspicion of preeclampsia. The sFlt-1/PlGF ratio was calculated from maternal serum concentrations measurements of both biomarkers in 144 women at the Hospital of Gynecology and Obstetrics, Unidad Medica de Alta Especialidad, Centro Medico Nacional de Occidente in Guadalajara, Jalisco, Mexico from April 2024-January 2026.

Results: Among 144 women included in the final analysis, 57 (39.5%) developed preeclampsia; 39 (68.4%) had early-onset and 18 (31.6%) late-onset preeclampsia. The median sFlt-1/PlGF ratio was higher in women who developed the disease than in those in the control group (98.65 vs 11.86; p<0.001). The diagnostic performance of the sFlt-1/PlGF ratio using a cut-off value≥38 to predict preeclampsia yielded a sensitivity of 73.68% (95% CI: 61.02-83.35) and specificity of 81.61% (95% CI: 72.19-88.35). Higher sFlt-1/PlGF ratios were also observed among pregnancies with adverse maternal or perinatal outcomes.

Conclusions: The sFlt-1/PlGF ratio demonstrated good discriminatory performance for preeclampsia and association with adverse maternal and perinatal outcomes in our cohort. The sFlt-1/PlGF ratio correlates accurately with prognostic value.

References

Phipps E, Thadhani R, Benzing T, Karumanchi S. Pre-eclampsia: pathogenesis, novel diagnostics and therapies. Nat Rev Nephrol. 2019;15(5):275-89.

Jung E, Romero R, Yeo L, Gomez-Lopez N, Chaemsaithong P, Jaovisidha A, et al. The etiology of preeclampsia. Am J Obstet Gynecol. 2022;226(2):S844-66.

Roberts J. Preeclampsia epidemiology(ies) and pathophysiology(ies). Best Pract Res Clin Obstet Gynaecol. 2024;94:102480.

Hoffman M, Goudar S, Kodkany B, Metgud M, Somannavar M, Okitawutshu J, et al. Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomized, double-blind, placebo-controlled trial. Lancet. 2020;395(10220):285-93.

Wei X, Yang X. The central role of natural killer cells in preeclampsia. Front Immunol. 2023;14:1009867.

Wu Y, Liu Y, Ding Y. Predictive performance of placental protein 13 for screening preeclampsia in the first trimester: a systematic review and meta-analysis. Front Med (Lausanne). 2021;8:756383.

Phipps E, Prasanna D, Brima W, Jim B. Preeclampsia: updates in pathogenesis, definitions, and guidelines. Clin J Am Soc Nephrol. 2016;11(6):1102-13.

Pereira M, Torrado J, Sosa C, Zócalo Y, Bia D. Role of arterial impairment in preeclampsia: should the paradigm shift? Am J Physiol Heart Circ Physiol. 2021;320(5):H2011-30.

Turbeville H, Sasser J. Preeclampsia beyond pregnancy: long-term consequences for mother and child. Am J Physiol Renal Physiol. 2020;318(6):F1315-26.

De Falco S. The discovery of placenta growth factor and its biological activity. Exp Mol Med. 2012;44(1):1-9.

Costa R, Hoshida M, Alves E, Zugaib M, Francisco R. Preeclampsia and superimposed preeclampsia: the same disease? The role of angiogenic biomarkers. Hypertens Pregnancy. 2016;35(2):139-49.

Sovio U, Gaccioli F, Cook E, Hund M, Charnock-Jones D, Smith G. Prediction of preeclampsia using the soluble fms-like tyrosine kinase 1 to placental growth factor ratio: a prospective cohort study of unselected nulliparous women. Hypertension. 2017;69(4):731-8.

Verlohren S, Herraiz I, Lapaire O, Schlembach D, Zeisler H, Calda P, et al. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension. 2014;63(2):346-52.

Zeisler H, Llurba E, Chantraine F, Vatish M, Staff A, Sennström M, et al. Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting. Ultrasound Obstet Gynecol. 2019;53(3):367-75.

Sabrià E, Lequerica-Fernández P, Ganuza P, Ángeles E, Escudero A, Martínez-Morillo E, et al. Use of the sFlt-1/PlGF ratio to rule out preeclampsia requiring delivery in women with suspected disease. Is the evidence reproducible? Clin Chemistry Laboratory Med. 2017;56(2):303-11.

Zeisler H, Llurba E, Chantraine F, Vatish M, Staff A, Sennström M, et al. Predictive value of the sFlt-1 ratio in women with suspected preeclampsia. N Engl J Med. 2016;374(1):13-22.

Pan X, Peng J, Chen Y. sFlt ‐1/ PlGF ratio thresholds for diagnosing pre‐eclampsia in pregnant women with high blood pressure. Ultrasound Obstet Gynecol. 2025;66(5):631-40.

Reddy M, Palmer K, Rolnik D, Wallace E, Mol B, Da Silva F. Role of placental, fetal and maternal cardiovascular markers in predicting adverse outcome in women with suspected or confirmed pre-eclampsia. Ultrasound Obstet Gynecol. 2022;59(5):596-605.

Kifle M, Dahal P, Vatish M, Cerdeira A, Ohuma E. The prognostic utility of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) biomarkers for predicting preeclampsia: a secondary analysis of data from the INSPIRE trial. BMC Pregnancy Childbirth. 2022;22:520.

Tătaru-Copos A, Huniadi A, Negrini R, Popescu M, Trif P, Murvai G, et al. sFlt-1/PlGF ratio as a central biomarker for preeclampsia and perinatal outcomes: a multisystem retrospective cohort study. J Clin Med. 2026;15(5):1990.

Lim S, Li W, Kemper J, Nguyen A, Mol BW, Reddy M. Biomarkers and the prediction of adverse outcomes in preeclampsia: a systematic review and meta-analysis. Obstet Gynecol. 2021;137(1):72-81.